

Respiratory medicine

Edited by Craig Davidson MD FRCP,
Consultant in Respiratory and Intensive Care Medicine,
St Thomas' Hospital, London

Oxygen therapy

Luke S Howard MA DPhil MRCP, Consultant Chest Physician, Department of Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust

Clin Med 2009;9:156–9

Oxygen delivery (DO_2) is arguably the most critical requirement for the maintenance of normal organ function and can be illustrated by Equation 1:

$$DO_2 = CaO_2 \times \text{cardiac output}$$

where CaO_2 is total oxygen content, made up largely of oxygen bound to haemoglobin and, to a much smaller degree, oxygen dissolved in plasma. DO_2 therefore depends not only on the degree of oxygenation of the blood but also on cardiovascular function and haemoglobin concentration. Despite its importance, it is not the most tightly regulated physiological parameter for metabolism and gas exchange. This is well illustrated by a study of repeated venesection resulting in isovolaemic anaemia (5 g/dl) in healthy humans.¹ While cardiac output rose, it was insufficient to maintain DO_2 but because of the steep slope of the oxyhaemoglobin dissociation curve at the tissue level, the fall in DO_2 was offset by increased oxygen extraction, indicated by a reduction in mixed venous oxygen (SvO_2).

SvO_2 is therefore a much better indicator of oxygen delivery than arterial saturation (SaO_2), and is one of the targets in resuscitation in sepsis. SaO_2 is readily measurable and helpful in resuscitation, although attention should be paid to integrated physiological function.²

The normal ranges of arterial oxygen tension (PaO_2) and SaO_2 are 10–13 kPa and 94–98%, respectively. It is apparent that DO_2 cannot be significantly enhanced by increasing PaO_2 above 16 kPa, where haemoglobin is 100% saturated and the amount of oxygen dissolved in the plasma is small. This manoeuvre will maximise CaO_2 but may not always optimise DO_2 .

Oxygen 'toxicity'

There are many reasons why maximising SaO_2 may firstly not optimise DO_2 and secondly may impact adversely on other aspects of a patient's physiology. The best-known example of this occurs during acute exacerbations of chronic obstructive pulmonary disease (COPD). Here PaO_2 above 10 kPa is associated with respiratory acidosis and worse outcomes.^{3,4} Decreased hypoxic drive, absorption atelectasis and the Haldane

effect (decreased CO_2 buffering by oxyhaemoglobin) all contribute to hypercapnia, but the greatest effect is likely to relate to worsened ventilation-perfusion mismatch. Deoxygenated pulmonary arterial blood is diverted away from areas of diseased lung because alveolar hypoxia due to poor ventilation causes vasoconstriction and thus decreased local perfusion (ie hypoxic pulmonary vasoconstriction). If high-flow oxygen is applied, these alveoli re-oxygenate and reperfuse, but remain poorly ventilated and fail to clear CO_2 . In reasonably healthy lungs, regional failure to clear CO_2 can be compensated by an overall increase in ventilation, but impaired respiratory mechanics prohibit this in COPD.

Other adverse effects of hyperoxia relate to effects on the cardiovascular system and the production of reactive oxygen species (discussed in detail elsewhere⁵). Table 1 summarises some of the concepts, with selected references. Hyperbaric oxygen therapy for stroke and intracoronary hyperoxaemic reperfusion for myocardial infarction (MI) are currently being explored. It is possible that the significant rise in oxygen tension in infarcted tissue may outweigh the physiological changes and oxidative stress, but these data are awaited. Studies of supra-physiological DO_2 in critical illness have so far failed to show benefit.¹⁰

Table 1. The adverse effects of hyperoxia achieved with normobaric oxygen.

Organ/System	Effect of hyperoxia
Pulmonary	<ul style="list-style-type: none"> • Absorption atelectasis • Release of hypoxic pulmonary vasoconstriction, leading to worsened ventilation/perfusion matching • Decreased ventilation • Pulmonary capillary leak – oxygen toxicity
Cardiovascular	<ul style="list-style-type: none"> • Coronary vasoconstriction • Increased systemic vascular resistance (increasing cardiac work) • Decreased cardiac output (decreasing O_2 delivery) • Reperfusion injury post-myocardial infarction⁶ • Worsened outcomes post-neonatal resuscitation⁷
Neurological	<ul style="list-style-type: none"> • Neuronal injury post-cardiac arrest in adults⁸ • Increased mortality following minor/moderate stroke⁹
Haematological	<ul style="list-style-type: none"> • Decreased CO_2 buffering by haemoglobin (Haldane effect)

Emergency oxygen use in adults

Guidelines

Recent guidelines for emergency oxygen in adults have been developed under the auspices of the British Thoracic Society (BTS) in association with 21 UK societies.⁵ In determining emergency oxygen policy, the committee felt two diametrically opposed philosophical positions could be assumed due to the paucity of evidence:

- 1 *Plentiful oxygen.* Maximising SaO₂ with high-concentration oxygen (HCO) is advisable in many situations, particularly in critical illness when monitoring is unavailable (eg at the roadside).

Even when saturations are being monitored, it may be appropriate as other contributors to DO₂ (Equation 1) may not yet be known. Furthermore, it can provide a margin of safety in the event of worsening gas exchange. However, this margin of safety may also mask deterioration¹¹ since saturations will fall only when the alveolar-arterial gradient is large or the PaO₂/fractional concentration of oxygen in inspired gas (FiO₂) ratio falls below 100. Other clinical features may flag deterioration, but patients who need increasing oxygen to maintain saturations may trigger warning systems earlier.

- 2 *Oxygen only when needed to achieve normal oxygen saturations,* given the absence of proven benefit of aiming higher and of concerns over the physiological and potentially toxic effects of hyperoxia.

The latter is the position taken by the committee. Notably, in the areas reviewed in Table 1, guidelines from other societies recommend administering oxygen to patients with stroke¹² and MI^{13,14} only in the event of hypoxaemia.

Consequently, the guidelines (Fig 1) recognise the necessity for HCO in critical illness, but in other situations recommend that oxygen is given only if saturations fall below the normal range (94–98%).⁵ Aligned with the Surviving Sepsis Campaign,¹⁵ the guidelines emphasise that maximised SaO₂ is not synonymous with optimised DO₂ and that vascular filling, haematocrit and cardiac output also need appropriate adjustment.

Exception is made, however, for patients at risk of hypercapnic respiratory




Fig 1. Initial algorithm for in-hospital prescription of oxygen. ABG = arterial blood gas; SpO₂ = peripheral oxygen saturation.⁵

Key Points

Optimisation of oxygen delivery requires more than oxygen therapy and attention should be paid to vascular filling, haematocrit and cardiac output

High-concentration oxygen may cause worse outcomes through physiological effects and reactive oxygen species

Emergency oxygen should be prescribed to a target saturation (88–92% in those at risk of hypercapnic respiratory failure, 94–98% in those not at risk), except in critical illness

Oxygen therapy at home should be assessed, prescribed and followed up by a specialised oxygen service, usually led by a respiratory physician in secondary care

In active patients, ambulatory oxygen should be prescribed to maintain saturations above 90%

KEY WORDS: chronic obstructive pulmonary disease, hypercapnia, hypoxaemia, oxygen, saturation

failure, typically patients with COPD, but also with neuromuscular and chest wall disorders. The recommended SaO_2 is 88–92%, based on observations that PaO_2 of 7.3–10 kPa is associated with the lowest incidence of acidosis.³ Patients known to be at risk of hypercapnic respiratory failure should be given an alert card with a prespecified saturation target range, usually 88–92%, although for some this may be lower. Arterial blood gases should guide further management as soon as they are available.

Overzealous withdrawal of HCO may do more harm than good through rebound hypoxaemia. This can be best understood through use of the alveolar gas equation (Equation 2):

$$\text{PAO}_2 \approx \text{PIO}_2 - \text{PACO}_2/\text{RER}$$

where RER is the respiratory exchange ratio of O_2 consumption to CO_2 production. When the partial pressure of inspired oxygen (PIO_2) is increased with

HCO, alveolar CO_2 (PACO_2) will rise. When PIO_2 is reduced to baseline, alveolar PO_2 (PAO_2) will therefore be lower than previously (until the CO_2 body stores are blown off). Consequently, arterial PaO_2 will be lower than prior to HCO. It can be considered conceptually as CO_2 occupying more ‘space’ in the alveolus. Thus, if an at-risk patient has been given HCO, oxygen should be withdrawn gradually, stepping down through fixed-concentration Venturi masks.

Criticisms of the guidelines

Following these guidelines, there is likely to be further argument about the risk of giving high or low levels of oxygen to patients with COPD. Critics of the lower saturation policy often quote a randomised pilot study of COPD exacerbations in which PaO_2 was titrated to 6.6 kPa in one group and 9 kPa in the other.¹⁶ There was a non-significant

trend to worse outcomes in the former group. It is beyond the scope of this article to enumerate all the reasons why this trial cannot be used to justify HCO in COPD exacerbations. One compelling factor, though, is that in neither group was PaO_2 allowed to rise significantly. It was therefore a trial comparing two levels of controlled oxygen. Furthermore, with regard to the effect of the degree of hypercapnic acidosis present in their population on the oxygen dissociation curve (the Bohr effect), target PaO_2 values of 6.6 kPa and 9 kPa theoretically translate to saturations of 74% and 89%, respectively. While, on average, the PaO_2 levels were higher than this, the higher target PaO_2 was actually much closer to the BTS recommendations.

A criticism often levelled at the controlled oxygen protagonist is that the sickest patients require higher concentration oxygen and for this reason there is an association with worse respiratory




Fig 2. Algorithm for prescription of long-term oxygen therapy (LTOT) and ambulatory oxygen. COPD = chronic obstructive pulmonary disease; PaO_2 = arterial oxygen tension; SpO_2 = peripheral oxygen saturation.

failure. Against this a study from Norwich showed that when a policy of giving 28% oxygen from the outset is instituted, there is no clear increase in complications or significant hypoxaemia.¹⁷ In addition, far fewer patients present with respiratory acidosis.

Oxygen at home

In 2006, a new policy for the prescription of home oxygen, to include long-term, ambulatory and short-burst treatments, was introduced by the Department of Health based on a report by the Royal College of Physicians in 1999.¹⁸ The two key components of the policy were to:

- rationalise oxygen providers, with groups of primary care trusts assigning contracts to one of four companies, and
- move the responsibility of oxygen assessment, prescription and follow up largely to secondary care, with patients assessed by a service directed by a respiratory physician. There is a requirement for a detailed prescription, consent form and record form by the service.

Long-term oxygen therapy

The criteria for long-term oxygen therapy (LTOT) for COPD have been extended to other long-term conditions (Fig 2). If nocturnal hypoventilation is suspected, formal assessment by a respiratory physician is necessary as non-invasive ventilation will be more appropriate in conditions such as neuromuscular and chest wall diseases, rather than oxygen. There is now greater access to ambulatory oxygen, but evidence suggests that, when it is prescribed, many patients use it rarely. A diary card should be provided with the first two-month supply to determine need for continuation.

Patients being assessed for ambulatory oxygen are subdivided into two groups:

- *low activity*: those who are usually immobile and need oxygen for leaving the home. They will need the same oxygen flow rate as their LTOT
- *active*: those likely to benefit from increased exercise capacity. Within

this group there will be patients on LTOT and some not, but who desaturate on exercise. Both subgroups should be assessed by six-minute or shuttle-walk testing to titrate the optimal flow rate and to assess the objective improvement in exercise capacity.

Ambulatory therapy is not indicated in chronic heart failure, but desaturation identifies coexistent pulmonary vascular disease and patients may benefit in this instance.

Short-burst therapy provided by cylinders kept in the home and used as required for the relief of breathlessness, may also be prescribed. A recent review, however, suggested little gain to patients with COPD and there is little clear guidance on who will benefit.¹⁹ It remains largely a clinical decision for the relief of breathlessness, but other palliative care approaches should also be considered.

References

- 1 Weiskopf RB, Viele MK, Feiner J *et al*. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. *JAMA* 1998;279:217–21.
- 2 Mak V. Respiratory failure: two forgotten concepts. *Clin Med* 2001;1:290–1.
- 3 Plant PK, Owen JL, Elliott MW. One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. *Thorax* 2000;55:550–4.
- 4 Plant PK, Owen JL, Elliott MW. Non-invasive ventilation in acute exacerbations of chronic obstructive pulmonary disease: long term survival and predictors of in-hospital outcome. *Thorax* 2001;56:708–12.
- 5 O'Driscoll BR, Howard LS, Davison AG. BTS guideline for emergency oxygen use in adult patients. *Thorax* 2008;63(Suppl 6): vi1–68.
- 6 Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocardial infarction. *BMJ* 1976;1:1121–3.
- 7 Davis PG, Tan A, O'Donnell CP, Schultze A. Resuscitation of newborn infants with 100% oxygen or air: a systematic review and meta-analysis. *Lancet* 2004;364: 1329–33.
- 8 Kuisma M, Boyd J, Voipio V *et al*. Comparison of 30 and the 100% inspired oxygen concentrations during early post-resuscitation period: a randomised controlled pilot study. *Resuscitation* 2006; 69:199–206.
- 9 Rønning OM, Guldvog B. Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. *Stroke* 1999;30:2033–7.
- 10 Velmahos GC, Demetriades D, Shoemaker WC *et al*. Endpoints of resuscitation of critically injured patients: normal or supranormal? A prospective randomized trial. *Ann Surg* 2000;232:409–18.
- 11 Downs JB. Has oxygen administration delayed appropriate respiratory care? Fallacies regarding oxygen therapy. *Respir Care* 2003;48:611–20.
- 12 Royal College of Physicians. *National clinical guideline for stroke*, 2nd edn. London: RCP, 2004.
- 13 Arntz HR, Bossaert L, Filippatos GS; European Resuscitation Council. European Resuscitation Council guidelines for resuscitation 2005. Section 5. Initial management of acute coronary syndromes. Review. *Resuscitation* 2005;67(Suppl 1): S87–96.
- 14 Scottish Intercollegiate Guidelines Network. *Acute coronary syndromes. A national clinical guideline*. Guideline No 93, 2007. www.sign.ac.uk/pdf/sign93.pdf
- 15 Dellinger RP, Levy MM, Carlet JM *et al*. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Intensive Care Med* 2008;34:17–60.
- 16 Gomersall CD, Joynt GM, Freebairn RC, Lai CK, Oh TE. Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. *Crit Care Med* 2002; 30:113–6.
- 17 Durrington HJ, Flubacher M, Ramsey CF, Howard LSGE, Harrison BDW. Initial oxygen management in patients with an exacerbation of chronic obstructive pulmonary disease. *QJM* 2005;98:499–504.
- 18 Royal College of Physicians. *Domiciliary oxygen therapy services. Clinical guidelines and advice for prescribers*. Report of a Working Party of the Royal College of Physicians. London: RCP, 1999. www.rcplondon.ac.uk/pubs/brochure.aspx?e=78
- 19 O'Driscoll BR. Short burst oxygen therapy in patients with COPD. *Monaldi Arch Chest Dis* 2008;69:70–4.